Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.04.2015 | original article | Ausgabe 7-8/2015

Wiener klinische Wochenschrift 7-8/2015

Use of PET-CT for the assessment of treatment results in patients with sarcoidosis

Wiener klinische Wochenschrift > Ausgabe 7-8/2015
MD Aysun Yakar, MD Fatih Yakar, MD Murat Sezer, MD Mehmet Bayram, MD Ezgi Başak Erdoğan, MD Didem Özkan, MD Hatice K. Özçelik, MD Prof. Dr. Levent Tabak


Background and aim

Sarcoidosis is a multisystem disease of unknown origin. Determining the involvement and the response to the treatment is important. The aim of this study was to identify the effects of methylprednisolone and indomethacine on metabolic activity and pulmonary function test parameters in patients with sarcoidosis.

Material and methods

A total of 24 pulmonary sarcoidosis patients were enrolled in the study. All the patients underwent spirometry and [18F]fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET-CT) scan before treatment and were divided into two groups according to the necessity of corticosteroid treatment or not. Patients who did not have corticosteroid indication were treated with indomethacine. Symptomatic patients and patients who did not respond to indomethacine treatment received methylprednisolone. Patients were followed up on a monthly basis to determine the response. FDG uptakes as the disease activity were re-evaluated before ending the treatment at the sixth month.


Mean age of patients (16 male, 8 female) was 39.79 (9.3) years. Besides mediastinum and pulmonary parenchyma, extrapulmonary sites were also involved in patients with pulmonary sarcoidosis (distant lymph nodes (upper abdominal, supraclavicular, inguinal, and axillary), liver, and spleen). Although maximum standard uptake values of methylprednisolone group regressed significantly (p < 0.001) after treatment, indomethacine group did not have significant regression (p = 0.345). Despite metabolic regressions, spirometry values of patients did not significantly increase (p > 0.005).


FDG PET-CT may be useful for determining activity and the efficacy of treatments. Methylprednisolone is effective in reducing metabolic activity but does not lead to improvement in functional parameters.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 7-8/2015

Wiener klinische Wochenschrift 7-8/2015 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Mitteilungen der Gesellschaft der Ärzte in Wien